New Buy Rating Was Given to Arcadia Biosciences (NASDAQ:RKDA)

June 20, 2018 - By Maria Brooks

Why Has H.C. Wainwright Given Arcadia Biosciences (NASDAQ:RKDA) a $20.0000 Price Target

Stock research analysts at H.C. Wainwright has a key Buy rating for Arcadia Biosciences (NASDAQ:RKDA). The firm has started coverage in a note revealed on 19 June. The TP gives upside of 141.25 % from the current price.

The stock decreased 1.31% or $0.11 during the last trading session, reaching $8.29. About 253,702 shares traded. Arcadia Biosciences, Inc. (NASDAQ:RKDA) has declined 28.71% since June 20, 2017 and is downtrending. It has underperformed by 41.28% the S&P500.

Arcadia Biosciences, Inc., an agricultural food ingredient company, develops and commercializes health and nutrition ingredient traits worldwide. The company has market cap of $39.58 million. The firm offers a suite of agricultural productivity traits, including nitrogen use efficiency, water use efficiency and drought tolerance, salinity tolerance, and herbicide tolerance traits. It currently has negative earnings. It also provides nutritional oils comprising gamma linolenic acid safflower oil to manufacturers of dietary and nutritional supplements, medical foods, dog food, and other products under the SONOVA brand; and arachidonic acid safflower oil that is used as an ingredient in infant nutrition products.

More important recent Arcadia Biosciences, Inc. (NASDAQ:RKDA) news were published by: Benzinga.com which released: “Benzinga Pro’s 5 Stocks To Watch Today” on June 19, 2018, also Benzinga.com published article titled: “21 Stocks Moving In Tuesday’s Pre-Market Session”, Benzinga.com published: “38 Stocks Moving In Tuesday’s Mid-Day Session” on June 19, 2018. More interesting news about Arcadia Biosciences, Inc. (NASDAQ:RKDA) was released by: Benzinga.com and their article: “Benzinga’s Top Upgrades, Downgrades For June 19, 2018” with publication date: June 19, 2018.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.